As expected, the European Medicines Agency's (EMA) special committee, the CHMP, has given a negative opinion on Alzheimer's treatment, Aduhelm, as Biogen proved unable to convince the authority to approve the drug as managed to do in the US.
Photo: POOL New/VIA REUTERS / X80003
by marketwire, translated by daniel pedersen
On Friday, Alzheimer's drug Aduhelm, which pharmaceutical firm Biogen is behind, has been rejected by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.
Epkinly has become the first and only subcutaneously administered T-cell engaging bispecific antibody approved in the US for the treatment of this patient population.
While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.
The success of Novo Nordisk’s Ozempic and Wegovy as well as blockbuster shots made by rival Eli Lilly has left some patients with diabetes struggling to continue their treatment.